Clinical-morphological features of lobular, nodular and diffuse forms of adenomyosis

Abstract

The purpose of the study was to investigate clinical, morphological and immunohistochemical features and pathogenetic interrelationship between focal, nodular and diffuse forms of adenomyosis. There was investigated surgical samples of removed uterines and their fragments; patients were divided into 3 groups, the 1st group was consisted of 16 cases with focal adenomyosis, the 2nd - 24 females with nodular form of adenomyosis, the 3rd - 21 female with diffuse form of adenomyosis. All patients were underwent general clinical examination, instrumental and laboratory observation with the aim of the verification of the diagnosis. There were executed macro- and microscopic immunohistochemical investigations of fragments of the tissue from the zone of endometrioid heterotopias, surrounding myometrium and eutopic endometrium. There were used antibodies: Ki-67, PTEN, ER, PR (“DAKO”), p16 (“Roshe”). There was established the significant increase in the expression of proliferation marker Ki-67, in parallel with a decrease in the expression level of PTEN, ER, PR from the focal to the nodular and diffuse forms of adenonomyosis. Thus it seems to be possible to consider focal, nodular and diffuse forms of adenomyosis as forms-phases of adenomyosis, that according both to histological characteristics of adenomyosis and immunohistochemical markers offocal and nodular forms may antedate the diffuse form of adenomyosis, that is also confirmed by the detection of a combination of all of these forms. Diffuse form of adenomyosis can be assumed to have the highest potential for the growth and dissemination of the pathological process in the uterine.

Keywords

forms-phases of adenomyosis / focal adenomyosis / nodular adenomyosis / diffuse adenomyosis / antibodies ER, PR, Ki-67, PTEN

References

[1] Кондриков Н.И. Патология матки. М.: Практическая медицина; 2008.

[2] Адамян Л.В., Кулаков В.И., Андреева Е.Н. Эндометриозы. М.: Медицина; 2006.

[3] Бурлев В.А., Ильясова Н.А., Гаврилова Т.Ю., Адамян Л.В. Дополнительные критерии оценки стадий распространения аденомиоза. Проблемы репродукции. 2006;(3): 47-52.

[4] Адамян Л.В., Андреева Е.Н. Клинико-генетические аспекты аденомиоза. Акуш. и гин. 1999;(3): 38-43.

[5] Sasa H., Imai K., Suzuki A., Sei K., Makimura N., Furuya K. Comparison of low-dose dienogest with low-dose danazol for longterm treatment of adenomyosis. Obstetr. and Gynecol. 2014; 123 (Suppl. 1): 97S-8S.

[6] Streuli I., Dubuisson J., Santulli P., de Ziegler D., Batteux F., Chapron C. An update on the pharmacological management of adenomyosis. Expert Opin. Pharmacother. 2014; 6:1-14.

[7] Zhou Y.F. Comprehensive understanding of adenomyosis. Zhonghua Fu Chan Ke Za Zhi. 2013; 48(4):291-4.

[8] Mehasseb M.K., Panchal R., Taylor A.H., Brown L., Bell S.C., Habiba M. Estrogen and progesterone receptor isoform distribution through the menstrual cycle in uteri with and without adenomyosis. Fertil. And Steril. 2011; 95(7):2228-35, 2235.e1.

[9] Копнин Б.П. Опухолевые супрессоры и мутаторные гены. В кн.: Заридзе Д.Г., ред. Канцерогенез. М.: Научный мир; 2000: 75-96.

[10] Grunwald V., DeGraffenried L., Russel D. et al. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 2002; 62: 6141-5.

[11] Cakmak H., Guzeloglu-Kayisli O., Kayisli U.A., Arici A. Immuneendocrine interactions in endometriosis. Front. in Biosc. 2009; El: 429-43.

[12] Коган Е.А., Парамонова Н.Б., Демура Т.А., Файзуллина Н.М., Овакимян А.С., Адамян Л.В. Морфологический субстрат и патогенетические механизмы синдрома тазовой боли при эндометриозе. Арх. пат. 2014; 76 (6): 37-43.

[13] Коган Е.А., Парамонова Н.Б., Низяева Н.В., Ежова Л.С., Файзуллина Н.М. Механизмы и пути генерализации эндометриоидной болезни. В кн.: Материалы VII Международного конгресса по репродуктивной медицине. М.; 2013 326-8.

RIGHTS & PERMISSIONS

Eco-Vector